World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Homepage

Online Submission

Number of total visits: 30558731

Number of visits today: 5396

Number of downloads: 12934167

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Yen YH, Chen CH, Hung CH, Wang JH, Lu SN, Kee KM, Hu TH. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data. PLoS One 2019;14:e0222605. [PMID: 31581209 DOI: 10.1371/journal.pone.0222605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]

For:

Yen YH, Chen CH, Hung CH, Wang JH, Lu SN, Kee KM, Hu TH. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data. PLoS One 2019;14:e0222605. [PMID: 31581209 DOI: 10.1371/journal.pone.0222605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]

Number	Citing Articles
1	Ridruejo E, Piñero F, Mendizabal M, Cheinquer H, Wolff FH, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, Zuain MGV, Tanno F, Figueroa S, Santos L, Peralta M, Soza A, Vistarini C, Adrover R, Fernández N, Perez D, Hernández N, Estepo C, Bruno A, Descalzi V, Sixto M, Borzi S, Cocozzella D, Zerega A, Araujo A, Varón A, Silva M; Latin American Liver Research Educational and Awareness Network (LALREAN). Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real‐world experience from HCV‐LALREAN cohort. J Med Virol 2020;92:3545-55. [DOI: 10.1002/jmv.26383] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2	Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association 2020;119:1135-57. [DOI: 10.1016/j.jfma.2020.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
3	Tsai WL, Wang CF, Cheng JS, Chen WC, Bair MJ, Lo CC. Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. PLoS One 2020;15:e0227424. [PMID: 31923251 DOI: 10.1371/journal.pone.0227424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4	Wong YJ, Thurairajah PH, Kumar R, Tan J, Fock KM, Law NM, Li W, Kwek A, Tan YB, Koh J, Lee ZC, Kumar LS, Teo EK, Ang TL. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. J Gastroenterol Hepatol. 2020;. [PMID: 33217040 DOI: 10.1111/jgh.15324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
5	Solitano V, Plaz Torres MC, Pugliese N, Aghemo A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses 2021;13:1048. [PMID: 34205966 DOI: 10.3390/v13061048] [Reference Citation Analysis]